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Diagnosis of de novo autoimmune hepatitis (AIH) after orthotopic liver transplantation (OLT) is challenging especially in the
absence of hyper-𝛾-globulinemia. Circulating autoantibodies are not sensitive nor specific in de novo AIH but when positive
increase the diagnostic probability. We report the discovery of novel liver microsomal (LM) autoantibodies against CYP-2C19
in a 9-year-old boy with “de novo” AIH developed 7 years after OLT. Graft dysfunction presented with hypertransaminasemia
(up to 400 IU/L), while serum 𝛾-globulins remained within the normal range for age. Liver histology and response to high
dose prednisone (2mg/kg/day) with the addition of azathioprine therapy further supported the diagnosis of de novo AIH.
Autoantibodies investigation by indirect immunofluorescence (IF) on rodent tissues showed a novel staining pattern involving
the pericentral liver zone and sparing the renal tissue. Human but not rat liver proteins immunoblotting allowed us to characterize
the novel LM antibodies and to identify CYP-2C19 as human antigen. The finding offers insights into the controversial discussion
about autoimmunity versus alloreactivity with regard to the pathogenesis of de novoAIH. Correct information on human versus rat
tissue antigens tested by methods other than IF for antibodies detection may have significant implications for the correct diagnosis
and management of patients followed up after OLT.
1. Introduction
De novo autoimmune hepatitis (AIH) after orthotopic liver
transplantation (OLT) should be suspected in any unex-
plained graft dysfunction, in both children and adults trans-
planted for an indication different from autoimmune liver
diseases [1, 2]. It is still not clear whether the pathogenesis
is autoimmune directed against the “self” or alloimmune
against the “non-self” after OLT. Passive transfer of autoan-
tibodies from the organ donor, induction by viral infection,
drug therapy, and ischemic injury of rejected transplanted
organ are the main hypothesized mechanisms [1, 2].
Differential diagnosis with the far more common graft
rejection and viral hepatitis is challenging in spite of the
diagnostic criteria for de novo AIH proposed in 2006 by the
Banff working group [3].
Both typical and atypical circulating autoantibodies have
been found to be associated with de novo AIH. Among
the typical ones [4, 5], anti-nuclear antibodies (ANA) have
been the most frequently detected (42.8%–100%), followed
Hindawi
BioMed Research International
Volume 2017, Article ID 3563278, 6 pages
https://doi.org/10.1155/2017/3563278
2 BioMed Research International
by anti-smooth muscle antibodies (SMA) (25%−50%), while
anti-liver/kidney microsomal antibodies (LKM) have been
detected more rarely. Atypical LKM antibodies are peculiar
for de novo AIH. They have been renamed anti-liver/kidney
cytosol (LKC) because they do not react with the liver
microsomes but with the cytosol and are specifically directed
against the cytosolic enzyme glutathione-S-transferase theta
1 (GTT1) [6, 7]. Autoantibodies against cytokeratins 8 and 18
(CK8-18) have been also detected in subjects with de novo
AIH [1, 8].
Here, we report for the first time in a child with de novo
AIH cytochrome P450 2C19 (CYP-2C19) as a hepatocellular
autoantigen of new liver microsomal (LM) autoantibodies.
LM against CYP-2C19 are different from the previously
described LM autoantibodies directed against CYP-1A2,
considered hallmark of AIH in children affected by Type 1
Autoimmune Polyglandular Syndrome (APS 1) [9–16].
2. Patient and Methods
2.1. Patient and Controls. The case is a 9-year-old boy who
developed evidence for de novo AIH, seven years after OLT
for biliary atresia. Controls included 50 healthy subjects and
66 nontransplanted patients affected by idiopathic autoim-
mune liver diseases: 11 with AH-1 (ANA and/or SMA posi-
tives), 11 with AH-2 (LKM-1 and/or LC-1 positives), 2 with
AH-3 (SLA positives), 26 with Primary Biliary Cholangitis
(PBC, AMA positives), and 16 with APS-1 (one LM positive,
five LKM positives).
2.2. Indirect Immunofluorescence (IF). Rat kidney, liver, and
stomach tissue sections were used for ANA, SMA, LKM,
and AMAdetection (SCIMEDX, Denville, New Jersey, USA),
and human epithelial type 2 (HEp-2) cells were used for
ANA, AMA, and anti-actin antibodies detection (MarDx
diagnostics, Carlsbad, California, USA). Briefly, slides were
incubated in moist chamber for 30 minutes with serum serial
dilutions (from 1 : 40 to 1 : 1280) at room temperature (RT).
Then they were washed twice for 5 minutes in phosphate
buffer saline (PBS) solution, incubated at RT for 30 minutes
with FITC-conjugated goat anti-human sera (IgA + IgG +
IgM, Medic, Castello di Pavone, TO, Italy), diluted 1 : 100 in
PBS, washed twice as before, and read with a fluorescence
microscope (Olympus BX51).
2.3. Immunoblotting (IB) with Rat and Human Liver Proteins.
IB experiments were carried out using both rat and human
liver tissues. Human liver was obtained during liver trans-
plantation from a reduced size donor liver whose material in
excess would be anyway discarded. Microsomal, mitochon-
drial, and soluble protein fractions from rat and human liver
were prepared by differential centrifugations and ultracen-
trifugations as described previously [11]. Rat and human liver
subcellular protein fractions (microsomal, mitochondrial,
and soluble) were separated in different experiments. Poly-
acrylamide gel electrophoresis (PAGE) was carried out under
denaturing conditions for rat proteins by sodium dodecyl
sulfate-PAGE (SDS-PAGE, 12%) while human proteins were
separated under not denaturing conditions PAGE (12%) in
absence of SDS. After electrophoresis, both rat and human
proteins were transferred from the gels onto nitrocellulose
filters as described previously [11, 12]. Filters were blocked for
1 hour in a PBS 0.1% Tween-20, 3% nonfat dry milk solution,
incubated for 1 hour at RT with patient sera at 1 : 100 dilution,
and successively incubated for 1 hour at RT with 1 : 1000 dilu-
tion of alkaline phosphatase conjugated anti-human IgG +
IgM+ IgA antiserum (ICNBiomedicals, Aurora, Ohio, USA).
The NBT-BCIP detection system (Bio-Rad, Hercules, CA,
USA) was used to develop the filters.
2.4. Immunoblotting (IB) with Six Human Recombinant CYPs
and UGT1. Baculovirus insect cell-expressed human hepatic
recombinant cytochrome P450s and UGT1 were purchased
from Gentest Corp. (Woburn, MA, USA) [12]. The IB assay
used was SDS-PAGE (12%), following the steps described in
Section 2.3.
3. Results
3.1. Clinical Report. A 9-year-old boy developed de novo
AIH 7 years after liver transplantation for biliary atresia. He
was under treatment with cyclosporine (CyA) (trough blood
levels of 151𝜇g/L). The immune-mediated graft dysfunction
occurred during prednisone (PDN) tapering/weaning dose
(from 5mg to 0mg/day) and presented with a progressive
increase of serum ALT (from <40 IU/L up to 400 IU/L) and
IgG (from 600mg/dl up to 1200mg/dl). Liver biopsy revealed
a histological picture of portal tracts enlarged by a dense
lymphoplasmacytic infiltrate and fibrosis, moderate interface
hepatitis with intralobular inflammation, and necrosis in
absence of relevant evidence for rejection (data not shown).
Different possible causes of liver dysfunction other than
graft rejection and AIH were ruled out by appropriate tests,
including serology andmolecular testing for hepatitis B virus,
hepatitis C virus, Cytomegalovirus, Epstein Barr virus, and
parvovirus B19; moreover, sonography and color Doppler
sonography were performed to rule out biliary and vascular
abnormalities. Globally, the patient diagnostic score was
within the “probable” range of AIH. BothALT and IgG serum
levels promptly responded (<40U/L and 800mg/dl, respec-
tively) to the increase in the PDN dosage up to 2mg/kg/day
and to additional treatment with azathioprine (1mg/kg/day),
further supporting the diagnosis of de novo AIH. During a
30-month-follow-up period, the patient relapsed after two
attempts of PDN tapering dose from 10 to 5mg/day.
3.2. Indirect Immunofluorescence (IF). Thepatient serumwas
negative for typical ANA, SMA, and LKM autoantibodies
associated with AIH. IF analysis showed a novel pattern,
involving prevalently the pericentral zone and extending to
the mid-lobule zone of the liver (Figure 1(a)), while sparing
the staining of the renal proximal tubular cells (Figure 1(b)).
This new IF pattern appeared distinct from that of atypical
LKM or LKC pattern which is characterized by hepatic and
renal proximal tubular cell fluorescence immunostaining [1],
detected also by our group in 3 out of 45 post-OLT cohort of
children [19].
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Figure 1: (a-b) Indirect immunofluorescence (IF) results using the patient serum diluted at 1 : 640 in phosphate buffered saline and overlaid
on rat liver (a) and kidney (b) sections (photomicrograph; lens 10x). For immune staining, a goat anti-human Ig FITC-conjugate antiserum
was used at 1 : 100 dilution. The new LM antibody staining pattern involved mainly hepatocytes of the pericentral zone ((a), white arrow
points to the central vein) and extended to the mid-lobule zone of the liver ((a), white circle, yellow arrows indicate the surrounding negative
zone) while sparing the renal proximal tubular cells ((b), white arrows). (c) Immunoblotting results using human liver microsomal proteins
separated in PAGE. Lane 1, LKM positive control serum from a patient affected by type 2 idiopathic AIH, main protein band recognized at
∼50 kD; lane 2, LM positive serum from the reported case affected by de novo AIH, main protein band recognized at >51 kD; lane 3, atypical
LKMpositive control serum fromapost-OLTpatient, no protein band recognized.Markers on the left indicate themolecularweight standards
in kilodaltons (kD). (d) Immunoblotting results using six recombinant cytochromes P450. Lanes from the left to the right: CYP-2D6, CYP-
2C9, CYP-2C19, CYP-1A2, CYP-2A6, and CYP-3A4. (A) Results observed using the LM positive serum from the reported case affected by
de novo AIH, autoantigen recognized: CYP-2C19. (B) Results observed using a LKM positive control serum from a patient affected by type 2
idiopathic AIH, autoantigen recognized: CYP-2D6. Markers on the left indicate the molecular weight standards in kilodaltons (kD).
3.3. Immunoblotting (IB) with Rat and Human Liver Proteins.
While no reactivity was observed in experiments with rat
liver proteins (data not shown), a positive reaction with a
protein band was observed above the 51 kDmolecular weight
standard in IB experiments performed with the microsomal
fraction of human liver (Figure 1(c)). No reactivity appeared
toward the other two liver protein fractions, the soluble and
the mitochondrial, of human liver (data not shown). The
peculiar aspects observed at IF and IB assays allowed us to
classify the novel antibodies as liver microsomal (LM).
3.4. Immunoblotting (IB) with Six Human Recombinant CYPs
and UGT1. In order to identify the main target antigen
of the novel LM antibodies observed in IF, we performed
IB analysis using several commercially available human
recombinant CYPs and UGTs (BD Gentest, http://www
.bdbiosciences.com) as previously described [12]. The serum
that was positive in IF for LM antibodies showed specific
reactivity with only one of the human recombinant CYPs
tested (Figure 1(d)), namely, the CYP-2C19, a protein of
55,9 kD molecular weight (NCBI number: NP 000760.1).
CYP-2C19 is one of the human liver microsomal enzymes
belonging to the 2C family of the cytochrome P450 super-
family.The same serumdidnot reactwith any otherCYPs and
UGTs (Figure 1(d)). During the 30months of follow-up for de
novo AIH, LM antibody titer significantly changed, decreas-
ing to negative under the max dose of immunosuppression,
while coming back at any flare of relapse.
Atypical LKM positive sera of our previously described
post-OLT patients [19] did not react against any of the CYPs
or UGTs, including CYP-2C19 (data not shown).
CYP-2C19 was then tested as a potential antigen in 24
control sera from patients with idiopathic AIH, 26 patients
with PBC, 16 patients with APS-1, and 50 healthy controls.
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Table 1: Studies investigating LM and LKC autoantibodies with more than one immunological assay in patients affected by AIH of different
etiologies. Studies are ordered by year of publication.
Reference Year Diagnosis Ab Assay: IF onliver/kidney
Assay other
than IF Target Ag (kD) Age of patients
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Manns et al. [10] 1990 AIH-APS-1 LM
Liver [+]
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Liver [+]
Kidney [−] IB human CYPs CYP 1A2
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Meloni et al. [16] 2012 AIH-APS-1 LM Liver [+]Kidney [−] IB human CYPs CYP1A2 Pediatric







Ag, antigen; AIH, autoimmune hepatitis; AIH-drug, drug-induced AIH; AIH-APS-1, Type 1 Polyglandular Syndrome associated AIH; CYP, cytochrome
P450; GSTT1, glutathione-S-transferase T1; IB, immunoblotting; 2D-IB, two-dimensional immunoblotting; ID, immunodiffusion; IF, immunofluorescence;
kD, kilodaltons of Ag molecular weight; LKC, liver kidney cytosol antibody; LM, liver microsomal antibody; LKM, liver and kidney microsomal antibody;
post-OLT AIH, postorthotopic liver transplantation “de novo” AIH; Pts, patients.
None of these sera showed a positive reaction with the CYP-
2C19 (data not shown).
4. Discussion
The precise mechanism underlying de novo AIH is still ob-
scure, and controversy exists about autoimmunity versus
alloreactivity for explaining this immune-mediated graft
dysfunction that can arise after an allogenic organ transplan-
tation [20]. On the other hand, a graft rejection afterOLTmay
mimic de novo AIH [20].
Circulating autoantibodies are a common finding after
OLT especially in children [1]. However, in some cases,
serum IgG levels or autoantibodies can be normal or absent,
respectively, making the understanding and the diagnosis of
de novo hepatitis quite challenging [1, 18, 21].
Our case had most of the features of de novo AIH,
including increasing serum 𝛾-globulins, even if the values
remained always within the normal range of reference for
his age. He was positive for circulating autoantibodies. At
IF screening, however, their fluorescence immunostaining
pattern appeared distinct from that of atypical LKM or LKC,
whose target is GSTT1, and from antibodies against CK 8-18
previously described in other series of de novo AIH [6–8].
The IB assay performed with human liver allowed us to
characterize the novel autoantibodies as LM because it is
directed toward the microsomal protein fraction and toward
a band identified as CYP-2C19.
To the best of our knowledge, LM in children has hitherto
been described only in the context of APS1-related AIH [9–
16]. We therefore carried out a review of literature data on
LM and LKC autoantibodies laboratory characterization per-
formed with at least one adjunctive assay besides traditional
IF screening.The results are shown in Table 1. During the past
25 years, nine articles have been published.The studies on the
characterization of LM autoantibodies reacting against the
hepatic CYP-1A2 regarded essentially adults suffering from
hydralazine-induced AIH [17] or children and adults affected
by AIH as part of APS-1 [9–16]. These studies used the same
assay represented by IB of human proteins to identify the tar-
get antigen, that is, human CYP-1A2. The three studies pub-
lished on the characterization of LKC autoantibodies were
carried out in adults suffering from de novo AIH. The first
study successfully identified GSTT1 as target antigen of LKC
by testing positive sera with human liver cDNA expression
library [6], the second used immunodiffusion assay exclu-
sively with rat liver cytosol proteins [18], and the third one
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used two-dimensional IB assay performed with rat proteins
to characterize both LKC and classical LKM-1 autoantibodies
[7].
Similar to what has happened in the CYP-1A2 identifi-
cation, in the present study, CYP-2C19 could be identified
as LM target antigen when IB was performed with human
liver microsomes, although the IF was performed on rodent
tissue. This apparent discrepancy of LM antibodies has been
explained by differences existing between the rat and human
CYPs’ structure [11, 17]. Rat CYPs would share only a few
conformational epitopes with the human enzyme, which are
preserved in IF but are lost during sample preparation in IB
[11, 17]. It implies that, in the case of rat tissue preparation
only, our patient could have been un/misdiagnosed, because
besides a positive IF we would have found amisleading nega-
tive IB.
As the target antigen is an enzyme of the cytochrome
P450 family, the novel LM antibodies detected in our case are
unlikely donor specific antibodies (DSA). DSA react either to
donor lymphocytes or to a panel of HLA antigen targets; their
production derives from a mismatch in the liver expressed
proteins [22]. DSA can lead to an alloimmune hepatitis
and have been reported to cause antibody mediated acute
rejection developing de novo after transplantation [1, 22].
Some studies reported high levels of DSA in up to 22% of liver
transplant recipients without increased incidence of acute
rejection [22].
A post-OLT graft dysfunction mimicking de novo AIH
has also been described when GSTT1 is an alloantigen
becoming a neo-self-antigen due to a mismatch between the
liver donor and recipient [23]. Rising against the “non-self”
liver, this graft dysfunction can be defined as an alloreactive
immune response rather than an autoimmune one. Subjects
who genetically do not express GSTT1 may develop an
immune reaction against GSTT1 after OLT, detected serolog-
ically with the appearance of atypical LKMor LKC antibodies
[23].The “non-self” alloreactive type of immune response has
been ruled out for anti-LKM-1 antibody, whose serum pos-
itivity has been reported in genetically CYP-2D6 extensive
metabolizer individuals affected by AIH-2 [5, 24], in whom
a sufficiently high CYP-2D6 expression level is thought to be
necessary to trigger autoimmunity [5].
Since about 3% of Caucasians lack CYP-2C19 entirely
[25], it could be speculated that, rather than a true AIH,
our patient developed an immune reaction against a “non-
self” protein, that is, CYP-2C19, expressed in the graft. Unfor-
tunately, we could neither test whether our patient and the
graft were genetically different with regard to CYP-2C19 to
verify the existence of a CYP-2C19 mismatch between donor
and recipient, nor test whether the CYP-2C19 was expressed
and functionally active in the native liver of our patient
similarly to CYP-2D6 in AIH-2 patients [24].
Several human liver cytochrome P450s have been
reported as autoantigens of the liver/kidney or liver micro-
somal (LKM or LM) autoantibodies associated with chronic
hepatitis of different etiologies, with very little overlap [4].
The IF pattern of each microsomal autoantibody will depend
on the specific target antigen, whose expression can be
variable from the pericentral to the periportal zone of the
hepatic lobule [4, 5]. It is important to note the report of
liver microsomal autoantibodies detected at IF for which
target antigens have been not yet identified [5].Therefore, the
identification of CYP-2C19 as a human hepatic autoantigen
adds one more enzyme to the existing list.
In spite of the continuous progress in discovering new
autoantibodies andnewautoantigens, etiology andpathogen-
esis are clear only for the drug-induced forms of AIH. By
binding covalently to its specific metabolizing enzyme, the
drug creates a new molecule that acts as a neoantigen and
triggers the autoimmune response in genetically predisposed
individuals [26]. CYP-2C19 is one of the most important
microsomal enzymes involved in hepatic drug biotransfor-
mation reactions [25]. The commonly used omeprazole, sev-
eral benzodiazepines, and many of the tricyclic antidepres-
sants are metabolized by CYP-2C19 [25]. Rifampin induces
CYP-2C19 activity, while the antidepressants fluvoxamine,
fluoxetine, and the antithrombotic Ticlopidine inhibit it [25].
In our case, however, the post-OLT history was negative for
the assumption of any drug known to bemetabolized byCYP-
2C19.After liver transplantation, our patient underwent treat-
ment with cyclosporine, a drug metabolized by CYP-3A4,
which was tested negative in our IB experiments, making
it unlikely that the novel LM antibodies were cyclosporine-
induced.
5. Conclusions
Thepresent study is the first report on novel LM autoantibod-
ies directed against CYP-2C19 in a child with de novo AIH.
Correct information on human versus rat tissue antigens
tested by methods other than IF for antibodies character-
ization may have significant implications for the correct
diagnosis andmanagement of patients followed up after OLT.
We were, however, not able to clarify whether the novel
LMautoantibodies here described aremarker of autoimmune
reactions against the “self” or they derived from alloimmune
reactions against the “non-self” after OLT. This study repre-
sents a pathfinder on this topic and warrants exploration in
more extensive future studies.
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